precision
biosciences
springworks
therapeutics
announce
clinical
collaboration
evaluate
combination
nirogacestat
patients
relapsed
refractory
multiple
myeloma
durham
stamford
globe
newswire
precision
biosciences
nasdaq
dtil
clinical
stage
biotechnology
developing
allogeneic
car
vivo
gene
correction
therapies
genome
editing
platform
springworks
therapeutics
nasdaq
swtx
biopharmaceutical
company
focused
developing
medicines
patients
severe
rare
diseases
cancer
today
announced
entered
clinical
trial
collaboration
agreement
per
agreement
precision
biosciences
investigational
allogeneic
chimeric
antigen
receptor
car
cell
therapy
candidate
targeting
maturation
antigen
bcma
evaluated
combination
nirogacestat
springworks
investigational
gamma
secretase
inhibitor
gsi
patients
relapsed
refractory
multiple
myeloma
based
recent
clinical
data
using
gsis
combination
therapies
exciting
combine
agents
patients
need
better
therapies
said
nina
shah
study
principal
investigator
associate
professor
department
medicine
university
california
san
francisco
look
forward
data
generated
investigational
study
see
plus
nirogacestat
improves
clinical
outcomes
patients
multiple
gamma
secretase
inhibition
shown
preclinically
enhance
activity
therapies
preventing
cleavage
shedding
bcma
surface
myeloma
cells
increases
cell
surface
density
bcma
reduces
levels
soluble
bcma
via
mechanism
nirogacestat
may
enhance
activity
emerging
clinical
data
also
suggest
gsi
may
increase
antitumor
efficacy
autologous
car
therapy
patients
relapsed
refractory
multiple
june
initiated
phase
clinical
trial
targets
bcma
treatment
relapsed
refractory
multiple
myeloma
demonstrated
activity
preclinical
disease
models
said
chris
heery
chief
medical
officer
precision
biosciences
preclinical
data
program
well
others
suggested
importance
gamma
secretase
inhibition
unlock
full
potential
bcma
targeted
therapies
look
forward
evaluating
terms
agreement
precision
biosciences
assume
development
costs
expanded
phase
study
include
nirogacestat
evaluate
safety
preliminary
clinical
activity
combination
therapy
precision
biosciences
springworks
form
joint
development
committee
oversee
clinical
study
expected
commence
first
half
pending
discussions
regulators
patients
multiple
myeloma
great
need
treatment
advances
said
saqib
islam
chief
executive
officer
springworks
therapeutics
continue
believe
nirogacestat
potential
become
cornerstone
bcma
combination
therapy
patients
pleased
work
precision
biosciences
leading
group
scientific
advisors
clinical
investigators
evaluate
combination
gamma
secretase
inhibitor
car
allogeneic
car
cell
therapy
candidate
evaluated
safety
preliminary
clinical
activity
phase
multicenter
nonrandomized
parallel
assignment
study
adults
relapsed
refractory
multiple
myeloma
starting
dose
x
car
cells
kg
body
weight
subsequent
cohorts
receiving
escalating
doses
maximum
dose
x
car
cells
kg
body
weight
company
third
car
candidate
advance
clinic
part
pipeline
optimized
allogeneic
car
therapies
derived
healthy
donors
modified
via
simultaneous
tcr
car
step
company
proprietary
genome
editing
technology
precision
biosciences
optimizes
car
therapy
candidates
immune
cell
expansion
body
maintaining
high
proportion
na√Øve
central
memory
car
cells
food
drug
administration
fda
recently
granted
fast
track
designation
treatment
relapsed
refractory
multiple
myeloma
fda
previously
granted
orphan
drug
designation
clinical
trial
conducted
multiple
sites
information
visit
study
identifier
number
nirogacestat
nirogacestat
investigational
oral
selective
small
molecule
gamma
secretase
inhibitor
phase
clinical
development
desmoid
tumors
rare
often
debilitating
disfiguring
tumors
gamma
secretase
cleaves
multiple
transmembrane
protein
complexes
including
notch
believed
play
role
activating
pathways
contribute
desmoid
tumor
growth
addition
gamma
secretase
shown
directly
cleave
bcma
resulting
release
bcma
extracellular
domain
ecd
cell
surface
inhibiting
gamma
secretase
bcma
preserved
increasing
target
density
reducing
levels
soluble
bcma
ecd
may
serve
decoy
receptors
therapies
nirogacestat
ability
enhance
activity
therapies
observed
preclinical
models
multiple
myeloma
springworks
evaluating
nirogacestat
bcma
potentiator
four
collaborations
bcma
developers
evaluate
nirogacestat
combinations
across
modalities
including
conjugate
two
car
cell
therapies
bispecific
antibody
addition
springworks
fred
hutchinson
cancer
research
center
entered
sponsored
research
agreement
characterize
ability
nirogacestat
modulate
bcma
potentiate
bcma
directed
therapies
using
variety
preclinical
multiple
myeloma
models
developed
researchers
fred
hutch
nirogacestat
received
orphan
drug
designation
food
drug
administration
fda
treatment
desmoid
tumors
june
european
commission
treatment
soft
tissue
sarcoma
september
fda
also
granted
fast
track
breakthrough
therapy
designations
treatment
adult
patients
progressive
unresectable
recurrent
refractory
desmoid
tumors
deep
fibromatosis
november
august
precision
biosciences
inc
precision
biosciences
clinical
stage
biotechnology
company
dedicated
improving
life
dtil
novel
proprietary
genome
editing
platform
arcus
highly
specific
versatile
genome
editing
platform
designed
therapeutic
safety
delivery
control
mind
using
arcus
company
pipeline
consists
multiple
car
immunotherapy
clinical
candidates
several
vivo
gene
correction
therapy
candidates
cure
genetic
infectious
diseases
adequate
treatments
exist
information
precision
biosciences
please
visit
springworks
therapeutics
springworks
biopharmaceutical
company
applying
precision
medicine
approach
acquiring
developing
commercializing
medicines
underserved
patient
populations
suffering
devastating
rare
diseases
cancer
springworks
differentiated
portfolio
small
molecule
targeted
oncology
product
candidates
advancing
two
potentially
registrational
clinical
trials
rare
tumor
types
well
several
programs
addressing
highly
prevalent
genetically
defined
cancers
springworks
strategic
approach
operational
excellence
clinical
development
enabled
rapidly
advance
two
lead
product
candidates
clinical
trials
simultaneously
entering
multiple
partnerships
industry
leaders
expand
portfolio
information
visit
follow
springworkstx
twitter
linkedin
precision
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
without
limitation
statements
regarding
company
timing
clinical
trials
results
therefrom
involving
expected
benefits
producing
clinical
trial
material
company
manufacturing
facility
cases
identify
statements
terms
anticipate
believe
could
expect
plan
intend
estimate
target
mission
may
would
could
target
project
predict
contemplate
potential
negative
thereof
similar
words
expressions
statements
based
management
current
expectations
beliefs
assumptions
information
currently
available
us
statements
subject
number
known
unknown
risks
uncertainties
assumptions
actual
results
may
differ
materially
expressed
implied
statements
due
various
important
factors
including
limited
ability
become
profitable
ability
procure
sufficient
funding
requirements
current
debt
instruments
operating
expenses
ability
predict
expenses
limited
operating
history
success
programs
product
candidates
expend
resources
dependence
arcus
technology
initiation
cost
timing
progress
achievement
milestones
results
research
development
activities
preclinical
greenhouse
studies
clinical
field
trials
public
perception
genome
editing
technology
applications
competition
genome
editing
biopharmaceutical
biotechnology
agricultural
biotechnology
fields
collaborators
ability
identify
develop
commercialize
product
candidates
pending
potential
liability
lawsuits
penalties
us
collaborators
related
technology
product
candidates
foreign
regulatory
landscape
applicable
collaborators
development
product
candidates
collaborators
ability
obtain
maintain
regulatory
approval
product
candidates
related
restrictions
limitations
warnings
label
approved
product
candidate
collaborators
ability
advance
product
candidates
successfully
design
implement
complete
clinical
field
trials
potential
manufacturing
problems
associated
development
commercialization
product
candidates
ability
achieve
anticipated
operating
efficiencies
manufacturing
facility
delays
difficulties
collaborators
ability
enroll
patients
product
candidates
work
intended
cause
undesirable
side
effects
risks
associated
applicable
healthcare
data
privacy
security
regulations
compliance
therewith
rate
degree
market
acceptance
product
candidates
success
existing
collaboration
agreements
ability
enter
new
collaboration
arrangements
current
future
relationships
third
parties
including
suppliers
manufacturers
ability
obtain
maintain
intellectual
property
protection
technology
product
candidates
potential
litigation
relating
infringement
misappropriation
intellectual
property
rights
ability
effectively
manage
growth
operations
ability
attract
retain
motivate
key
scientific
management
personnel
market
economic
conditions
effects
natural
manmade
disasters
public
health
emergencies
natural
catastrophic
events
effects
outbreak
pandemic
epidemic
outbreak
infectious
disease
insurance
expenses
exposure
uninsured
liabilities
important
factors
discussed
caption
risk
factors
quarterly
report
form
quarterly
period
ended
june
factors
may
updated
time
time
filings
sec
accessible
sec
website
investors
media
page
website
statements
speak
date
press
release
except
required
applicable
law
plan
publicly
update
revise
statements
contained
herein
whether
result
new
information
future
events
changed
circumstances
otherwise
springworks
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
statements
regarding
springworks
clinical
trials
strategy
business
plans
focus
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
related
springworks
financial
results
timing
completion
springworks
clinical
trials
product
candidates
whether
springworks
product
candidates
receive
approval
food
drug
administration
fda
foreign
regulatory
authorities
uncertainties
assumptions
regarding
impact
pandemic
springworks
business
operations
clinical
trials
supply
chain
strategy
goals
anticipated
timelines
competition
biopharmaceutical
companies
risks
identified
section
entitled
risk
factors
item
part
ii
springworks
quarterly
report
form
quarter
ended
june
well
discussions
potential
risks
uncertainties
important
factors
springworks
subsequent
filings
securities
exchange
commission
springworks
cautions
place
undue
reliance
statements
speak
date
made
springworks
disclaims
obligation
publicly
update
revise
statements
reflect
change
expectations
events
conditions
circumstances
statements
may
based
may
affect
likelihood
actual
results
differ
set
forth
statements
statements
contained
press
release
represent
springworks
views
date
hereof
relied
upon
representing
views
subsequent
date
contact
maurissa
messier
senior
director
corporate
communications
kim
diamond
vice
president
communications
investor
relations
kdiamond
references
eastman
shelton
c
gupta
krueger
j
blackwell
c
bojczuk
synergistic
activity
belantamab
mafodotin
inhibitor
cancer
cell
lines
blood
cowan
aj
pont
sather
bd
et
al
efficacy
safety
fully
human
bcma
car
cells
combination
gamma
secretase
inhibitor
increase
bcma
surface
expression
patients
relapsed
refractory
multiple
myeloma
blood
pont
mj
hill
cole
go
et
al
inhibition
increases
efficacy
chimeric
antigen
receptor
cells
multiple
myeloma
blood
